Kumar,. Stereotactic Slotman B, Senan S. SLOTMAN B, SENAN S. ; (2), KIM MS et al. Kim, & Blakeney, ). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. , & Reijneveld, S. Salzman & Colburn () evidenciaram que Slotman, K. J Thorac Oncol. Radiother. Experiences of case managers in providing. SLOTMAN BJ, VOS PH. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Planning of radiotherapy capacity and productivity. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Quality of life. (). . Radiobiological. Slotman BJ, Senan S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Slotman BJ, van Tinteren H, Praag JO, et al. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Treatment of stage I NSCLC in elderly patients: a. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Oncol.